Although the role of pharmacotherapy is currently ill-defined [5], a phase II trial is currently investigating the efficacy of targeted therapies in meningiomas harboring specific, targetable alterations, including SMO/AKT/NF2/CDK mutations (NCT02523014). This evidence concerns the gene AKT1 and meningioma.